MarketCap
Kala Pharmaceuticals KALA
$ 0.17
-5.56%
Facebook
X
Telegram
Kala Pharmaceuticals Total Liabilities | KALA
Annual Total Liabilities Kala Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.49 M | 43.2 M | 48.4 M | 67.8 M | 123 M | 122 M | 125 M | 116 M | 26.5 M | 134 M | 65.1 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | 2.49 M | 79.3 M |
Quarterly Total Liabilities Kala Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.49 M | 1.56 M | 43.2 M | 33.7 M | 39.3 M | 42.5 M | 43.2 M | 47.2 M | 47.9 M | 46.4 M | 48.4 M | 49.9 M | 49 M | 48.8 M | 67.8 M | 86.7 M | 117 M | 117 M | 123 M | 132 M | 131 M | 120 M | 122 M | 122 M | 122 M | 122 M | 125 M | 125 M | 125 M | 125 M | 116 M | 116 M | 116 M | 116 M | 26.9 M | 26.9 M | 26.9 M | 26.9 M | 15.7 M | 15.7 M | 15.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 132 M | 1.56 M | 74.2 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Curis
CRIS
|
14.5 M | $ 0.59 | -9.62 % | $ 7.77 M |  USA |
 |
Cyclerion Therapeutics
CYCN
|
55.9 M | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Fusion Pharmaceuticals
FUSN
|
63.4 M | - | - | $ 1.41 B |  Canada |
 |
Завод ДИОД
DIOD
|
195 M | - | - | - |  Russia |
 |
Gritstone Oncology
GRTS
|
126 M | - | 0.42 % | $ 213 M | USA |
 |
Pfizer
PFE
|
121 B | $ 29.42 | 0.19 % | $ 167 B | USA |
 |
HOOKIPA Pharma
HOOK
|
31.3 M | - | -6.92 % | $ 79.4 M | USA |
 |
Guardion Health Sciences
GHSI
|
3.77 M | - | -0.31 % | $ 3.64 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
23.6 M | - | - | $ 109 M | USA |
 |
Monopar Therapeutics
MNPR
|
2.89 M | $ 71.83 | 0.07 % | $ 532 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Otonomy
OTIC
|
40.7 M | - | -1.96 % | $ 4.68 M | USA |
 |
Prothena Corporation plc
PRTA
|
46.3 M | $ 8.74 | 2.1 % | $ 470 M | USA |
 |
Exelixis
EXEL
|
683 M | $ 70.73 | 0.21 % | $ 19.2 B | USA |
 |
Aridis Pharmaceuticals
ARDS
|
38.9 M | - | 17.91 % | $ 11.1 M | USA |
 |
Фармсинтез
LIFE
|
1.04 B | - | - | - | Russia |
 |
Arcus Biosciences
RCUS
|
39.3 M | $ 18.83 | 0.86 % | $ 2.02 B | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
156 B | $ 14.79 | -0.57 % | $ 12.3 B |  India |
 |
Oncternal Therapeutics
ONCT
|
6.68 M | - | -24.12 % | $ 1.56 M | USA |
 |
Iterum Therapeutics
ITRM
|
48.7 M | - | - | $ 591 K |  Irlanda |
 |
Royalty Pharma plc
RPRX
|
9.91 B | $ 70.01 | 0.81 % | $ 30.1 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
210 M | $ 114.06 | 0.1 % | $ 7.41 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
SIGA Technologies
SIGA
|
20.6 M | $ 3.17 | 0.32 % | $ 227 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
53.1 M | - | - | $ 401 M | USA |
 |
ImmunoGen
IMGN
|
193 M | - | - | $ 7.92 B | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
4.43 M | - | -8.77 % | $ 12.4 M |  Israel |
 |
Histogen
HSTO
|
5.7 M | - | 31.6 % | $ 2.12 M | USA |
 |
Summit Therapeutics
SMMT
|
92.3 M | $ 16.64 | -6.7 % | $ 12.4 B |  Britain |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Cidara Therapeutics
CDTX
|
51.5 M | - | - | $ 1.41 B | USA |
 |
Syndax Pharmaceuticals
SNDX
|
465 M | $ 9.59 | 1.05 % | $ 831 M | USA |
 |
Scholar Rock Holding Corporation
SRRK
|
159 M | $ 46.66 | -2.8 % | $ 5.35 B | USA |
 |
Clovis Oncology
CLVS
|
752 M | - | -7.23 % | $ 13 M | USA |
|
Protara Therapeutics
TARA
|
13.1 M | $ 2.61 | 7.41 % | $ 112 M | USA |
 |
Tarsus Pharmaceuticals
TARS
|
219 M | $ 76.79 | 4.0 % | $ 3.21 B | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
405 M | - | - | $ 1.62 B | Israel |
 |
Bio-Techne Corporation
TECH
|
719 M | $ 72.8 | -0.03 % | $ 11.4 B | USA |
 |
Cabaletta Bio
CABA
|
53 M | $ 1.46 | 0.69 % | $ 147 M | USA |
 |
Gilead Sciences
GILD
|
39 B | $ 169.72 | -0.67 % | $ 211 B | USA |
 |
PhaseBio Pharmaceuticals
PHAS
|
154 M | - | 7.4 % | $ 6.29 M | USA |
 |
Forma Therapeutics Holdings
FMTX
|
62.7 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
881 M | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
2.25 B | - | - | $ 26.6 B | Irlanda |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
32 M | $ 3.86 | -5.98 % | $ 32.9 M | USA |
 |
Gossamer Bio
GOSS
|
295 M | $ 11.6 | 2.84 % | $ 2.65 B | USA |
 |
Provention Bio
PRVB
|
115 M | - | - | $ 2.37 B | USA |
 |
DBV Technologies S.A.
DBVT
|
64.9 M | $ 11.85 | 2.95 % | $ 1.65 B |  France |
 |
Taysha Gene Therapies
TSHA
|
96.4 M | $ 4.26 | -0.35 % | $ 1.36 B | USA |
 |
Reata Pharmaceuticals
RETA
|
426 M | - | - | $ 6.29 B | USA |